Reteplase contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>: | Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>: | ||
'''*Active internal [[bleeding]] | '''*Active internal [[bleeding]]''' | ||
*History of [[cerebrovascular accident]] | '''*History of [[cerebrovascular accident]]''' | ||
*Recent intracranial or intraspinal surgery or trauma (see [[Reteplase warnings|WARNINGS]]) | '''*Recent intracranial or intraspinal surgery or trauma (see [[Reteplase warnings and precautions|WARNINGS]])''' | ||
*Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]] | '''*Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]]''' | ||
*Known bleeding [[diathesis]] | '''*Known bleeding [[diathesis]]''' | ||
*Severe uncontrolled [[hypertension]]'''<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>: | '''*Severe uncontrolled [[hypertension]]'''<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 05:27, 4 March 2014
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations[1]:
*Active internal bleeding *History of cerebrovascular accident *Recent intracranial or intraspinal surgery or trauma (see WARNINGS) *Intracranial neoplasm, arteriovenous malformation, or aneurysm *Known bleeding diathesis *Severe uncontrolled hypertension[1]:
References
Adapted from the FDA Package Insert.